Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3779)	10/19/1999 9:07:00 AM
From: BMcV	Read Replies (1) \| Respond to of 10280

from Chirex's earnings report, any guesses as to which products are involved?: "Sepracor Agreements ChiRex announced today agreements with Sepracor Inc. to produce active ingredients for three Sepracor products at full-scale in the Annan 3 production building in Annan, Scotland. Technology transfer and scale-up has commenced on the first two products and the third product will commence during the fourth quarter of 1999. ChiRex expects to produce validation quantities of all three products during 2000, and expects to produce commercial quantities in 2001. The Sepracor agreements are significant because they represent the first production volumes in management's previously-announced strategy to utilize the Annan 3 production building. The Annan 3 production building was opened by Glaxo in 1989 at a cost of approximately $50 million and was a strategic manufacturing location in the Ranitidine (Zantac) supply chain. ChiRex acquired the Annan site and the underutilized Annan 3 capability from GlaxoWellcome in 1997." biz.yahoo.com